Brazil · Delayed Price · Currency is BRL Diagnósticos da América Earnings Call Transcripts
Fiscal Year 2026
-
Q3 delivered BRL 173m net income, stronger cash generation and lower debt, alongside continued revenue and volume growth. Margin expansion remains a focus, while Rede Américas comparisons were affected by extraordinary items.
-
Revenue grew 9.2% year-over-year to BRL 2.2 billion, with EBITDA up 53% and margin expanding to 21%. Operational efficiency, deleveraging, and innovation drove results, while cash flow and leverage improved. Positive outlook for H2 with continued growth and selective expansion.
-
Q1 2026 saw strong revenue and EBITDA growth, margin expansion, and improved cash flow, driven by diagnostics, premium, and home care segments. Leverage and CapEx were reduced, with investments focused on technology and efficiency. Premium and B2B channels remain key growth drivers.
Fiscal Year 2025
-
2025 saw a strategic turnaround with portfolio simplification, strong diagnostics growth, margin expansion, and significant deleveraging. Recurring EBITDA rose 21% in Q4, free cash flow grew 75% for the year, and the company enters 2026 with a robust outlook and disciplined capital allocation.
-
Q3 2025 saw robust revenue and margin growth, driven by diagnostics, premium, and B2B segments, with operational cash flow more than doubling year-over-year. Strategic divestments and disciplined capital management reduced leverage, while new services and digital initiatives supported ongoing efficiency gains.
-
Rede Américas JV drove a BRL 3.4B net debt reduction and refocused the business on diagnostics, with 5% revenue and 8% EBITDA growth year-over-year. Leverage fell to 2.82x, and operational improvements, SG&A optimization, and brand integration are expected to further enhance margins and cash generation.
-
Record first-quarter EBITDA and net income were achieved, driven by operational improvements and strategic focus. The joint venture with Amil reduced net debt and positions the company for further margin expansion and growth in diagnostics and oncology.
Fiscal Year 2024
-
EBITDA grew 11% to BRL 2.5 billion in 2024, driven by operational excellence, cost controls, and strategic repositioning. Leverage declined, cash generation improved, and the JV with Amil advanced, with further margin and efficiency gains expected.
-
Operational efficiency and margin focus drove 14% EBITDA growth and 6% revenue increase year-over-year, while strict investment discipline and asset sales contributed to a 20% reduction in leverage. Ongoing restructuring and process optimization are expected to further improve margins and capital structure.
-
Q2 2024 saw strong revenue and EBITDA growth, margin expansion, and stable net debt, supported by a BRL 1.5 billion capital injection and operational improvements. The company advanced on asset optimization, deleveraging, and expects further gains from the Amil transaction and asset sales.